{"id":33719,"date":"2023-09-08T10:52:10","date_gmt":"2023-09-08T05:22:10","guid":{"rendered":"https:\/\/flattrade.in\/kosh\/?p=33719"},"modified":"2023-09-08T11:01:33","modified_gmt":"2023-09-08T05:31:33","slug":"us-business-to-support-domestic-pharma-firms-growth-and-profitability-report","status":"publish","type":"post","link":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/","title":{"rendered":"US business to support domestic pharma firms\u2019 growth and profitability: Report"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"33719\" class=\"elementor elementor-33719\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-1accdbfa elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"1accdbfa\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-17b72d26\" data-id=\"17b72d26\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5eb1aa09 elementor-widget elementor-widget-text-editor\" data-id=\"5eb1aa09\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Indian pharma companies are expected to continue their growth momentum and profitability in US, helped by new product launches, ongoing drug shortages and growth opportunities in the domestic formulation business, according to rating agency India Ratings and Research (Ind-Ra).<\/p>\n<p>The pharmaceutical companies rated by Ind-Ra reported a robust revenue growth in Q1FY24 on account of new launches and a strong demand from the US due to ongoing drug shortages as well as European business. Overall, the topline grew 16.5% YoY in the first quarter of FY24, compared to 14.4% growth in Q4FY23.<\/p>\n<p>Domestic formulations, active pharmaceuticals ingredients (API), Europe and rest of the world (RoW) business grew at 6.2%, 8.7%, 19.9% and 8.5%, respectively, on a yearly basis in 1QFY24. The EBITDA margin of the rated companies rose by 518bp YoY to 23.4% in 1QFY24 compared to 20.6% YOY Q4FY23, led by a decline in raw material cost and lower freight costs. In addition, contributions from high-margin niche launches and easing of pricing pressure in the US market helped the companies\u2019 growth.<\/p>\n<p>Moreover, the rating agency stated that normalisation of drug prices in the US and lower raw material prices are expected to support the company in registering a revenue growth of 10% and EBITDA margin of about 21% during FY24. Ind-Ra said that the results in Q1FY24 provided an early indication of the easing and the trend is likely to sustain for the remainder of the financial year. However, the sustainability of growth beyond FY24 would depend on the performance of the US generic business. Meanwhile, Ind-Ra expects inspections by the US drug regulator to increase in FY24, but it is unlikely to cause any significant disruptions to pharma companies.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-276e6292 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"276e6292\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1590587a\" data-id=\"1590587a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7cd6dd7a elementor-widget elementor-widget-heading\" data-id=\"7cd6dd7a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Revenue Mix<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-520e1fa0 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"520e1fa0\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6739c769\" data-id=\"6739c769\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6a69e92a elementor-widget elementor-widget-text-editor\" data-id=\"6a69e92a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The rating agency said that the Indian formulations business to grow 10%-11% YoY in FY24, led by price and new launches growth. The companies in the domestic formulation business reported a revenue growth of 6.2% YoY on an aggregate basis, despite lower growth in the acute therapy segment and price impact, on the back of higher prices and strong traction in the chronic segment in Q1FY24.<\/p><p>The US business of domestic pharma companies continued to report strong growth at 26.6% YoY in Q1FY24 as against 12.4% YoY in Q4FY23, due to the launch of generic niche Revlimid, ongoing drugs shortages, easing pricing pressure. The rating agency expects stabilization in price erosion in the US business for the rest of fiscal 2024.<\/p><p>Further, the rating agency said that API manufacturing companies\u2019 revenue growth moderated to 8.7% YoY in Q1FY24 as against 15.2% YoY in 4QFY23. The rating agency also added that their EBITDA margins will remain so due to a moderation in API prices. Ind-Ra rated API companies have shown a mixed performance during the quarter.<\/p><p>Sales growth stood at 8.5% YoY in its rest of the world business in Q1FY24. The companies have shown a mixed performance, while the Europe business continue to deliver strong growth momentum in the quarter.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-1632e2a3 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"1632e2a3\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6d5f6512\" data-id=\"6d5f6512\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2fb4eea5 elementor-align-center elementor-widget elementor-widget-button\" data-id=\"2fb4eea5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/ekyc.flattrade.in\/openaccount\/?utm_source=Blog&#038;utm_medium=organic&#038;utm_campaign=Demat+Account\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Open a Free Demat Account<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"Indian pharma companies are expected to continue their growth momentum and profitability in US, helped by new product&hellip;","protected":false},"author":5,"featured_media":33725,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"csco_display_header_overlay":false,"csco_singular_sidebar":"","csco_page_header_type":"","csco_page_load_nextpost":"","csco_post_video_location":[],"csco_post_video_location_hash":"","csco_post_video_url":"","csco_post_video_bg_start_time":0,"csco_post_video_bg_end_time":0,"csco_post_video_bg_volume":false,"footnotes":""},"categories":[65],"tags":[46,43,95,78,139,48,26,692,144,267,389,693,77,47,24,23,84,21],"class_list":{"0":"post-33719","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-industry","8":"tag-market-news","9":"tag-market-update","10":"tag-markets","11":"tag-nifty","12":"tag-nifty-futures","13":"tag-nifty-today","14":"tag-nse","15":"tag-opening-bell","16":"tag-options","17":"tag-pharma","18":"tag-pharmaceuticals","19":"tag-pre-market","20":"tag-sensex","21":"tag-sensex-today","22":"tag-share-market","23":"tag-stock-market","24":"tag-stocks","25":"tag-trading-account","26":"cs-entry","27":"cs-video-wrap"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>US business to support domestic pharma firms\u2019 growth and profitability: Report - Flattrade Kosh<\/title>\n<meta name=\"description\" content=\"The pharmaceutical companies rated by Ind-Ra reported a robust revenue growth in Q1FY24 on account of new launches and a strong demand from the US due to ongoing drug shortages as well as European business.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"US business to support domestic pharma firms\u2019 growth and profitability: Report - Flattrade Kosh\" \/>\n<meta property=\"og:description\" content=\"The pharmaceutical companies rated by Ind-Ra reported a robust revenue growth in Q1FY24 on account of new launches and a strong demand from the US due to ongoing drug shortages as well as European business.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Flattrade Kosh\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-08T05:22:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-08T05:31:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Flattrade\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Flattrade\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/\"},\"author\":{\"name\":\"Flattrade\",\"@id\":\"https:\/\/flattrade.in\/kosh\/#\/schema\/person\/0df49afdcdc9b8cf2e54f80cbc763e04\"},\"headline\":\"US business to support domestic pharma firms\u2019 growth and profitability: Report\",\"datePublished\":\"2023-09-08T05:22:10+00:00\",\"dateModified\":\"2023-09-08T05:31:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/\"},\"wordCount\":501,\"image\":{\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg\",\"keywords\":[\"Market News\",\"Market Update\",\"Markets\",\"nifty\",\"nifty futures\",\"Nifty Today\",\"NSE\",\"Opening Bell\",\"options\",\"PHARMA\",\"Pharmaceuticals\",\"Pre Market\",\"sensex\",\"SENSEX Today\",\"Share Market\",\"Stock Market\",\"stocks\",\"Trading Account\"],\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/\",\"url\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/\",\"name\":\"US business to support domestic pharma firms\u2019 growth and profitability: Report - Flattrade Kosh\",\"isPartOf\":{\"@id\":\"https:\/\/flattrade.in\/kosh\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg\",\"datePublished\":\"2023-09-08T05:22:10+00:00\",\"dateModified\":\"2023-09-08T05:31:33+00:00\",\"author\":{\"@id\":\"https:\/\/flattrade.in\/kosh\/#\/schema\/person\/0df49afdcdc9b8cf2e54f80cbc763e04\"},\"description\":\"The pharmaceutical companies rated by Ind-Ra reported a robust revenue growth in Q1FY24 on account of new launches and a strong demand from the US due to ongoing drug shortages as well as European business.\",\"breadcrumb\":{\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#primaryimage\",\"url\":\"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg\",\"contentUrl\":\"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/flattrade.in\/kosh\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"US business to support domestic pharma firms\u2019 growth and profitability: Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/flattrade.in\/kosh\/#website\",\"url\":\"https:\/\/flattrade.in\/kosh\/\",\"name\":\"Flattrade Kosh\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/flattrade.in\/kosh\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/flattrade.in\/kosh\/#\/schema\/person\/0df49afdcdc9b8cf2e54f80cbc763e04\",\"name\":\"Flattrade\",\"url\":\"https:\/\/flattrade.in\/kosh\/author\/siddharth-aflattrade-in\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"US business to support domestic pharma firms\u2019 growth and profitability: Report - Flattrade Kosh","description":"The pharmaceutical companies rated by Ind-Ra reported a robust revenue growth in Q1FY24 on account of new launches and a strong demand from the US due to ongoing drug shortages as well as European business.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/","og_locale":"en_US","og_type":"article","og_title":"US business to support domestic pharma firms\u2019 growth and profitability: Report - Flattrade Kosh","og_description":"The pharmaceutical companies rated by Ind-Ra reported a robust revenue growth in Q1FY24 on account of new launches and a strong demand from the US due to ongoing drug shortages as well as European business.","og_url":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/","og_site_name":"Flattrade Kosh","article_published_time":"2023-09-08T05:22:10+00:00","article_modified_time":"2023-09-08T05:31:33+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg","type":"image\/jpeg"}],"author":"Flattrade","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Flattrade","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#article","isPartOf":{"@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/"},"author":{"name":"Flattrade","@id":"https:\/\/flattrade.in\/kosh\/#\/schema\/person\/0df49afdcdc9b8cf2e54f80cbc763e04"},"headline":"US business to support domestic pharma firms\u2019 growth and profitability: Report","datePublished":"2023-09-08T05:22:10+00:00","dateModified":"2023-09-08T05:31:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/"},"wordCount":501,"image":{"@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#primaryimage"},"thumbnailUrl":"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg","keywords":["Market News","Market Update","Markets","nifty","nifty futures","Nifty Today","NSE","Opening Bell","options","PHARMA","Pharmaceuticals","Pre Market","sensex","SENSEX Today","Share Market","Stock Market","stocks","Trading Account"],"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/","url":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/","name":"US business to support domestic pharma firms\u2019 growth and profitability: Report - Flattrade Kosh","isPartOf":{"@id":"https:\/\/flattrade.in\/kosh\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#primaryimage"},"image":{"@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#primaryimage"},"thumbnailUrl":"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg","datePublished":"2023-09-08T05:22:10+00:00","dateModified":"2023-09-08T05:31:33+00:00","author":{"@id":"https:\/\/flattrade.in\/kosh\/#\/schema\/person\/0df49afdcdc9b8cf2e54f80cbc763e04"},"description":"The pharmaceutical companies rated by Ind-Ra reported a robust revenue growth in Q1FY24 on account of new launches and a strong demand from the US due to ongoing drug shortages as well as European business.","breadcrumb":{"@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#primaryimage","url":"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg","contentUrl":"https:\/\/flattrade.in\/kosh\/wp-content\/uploads\/2023\/09\/pharma.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/flattrade.in\/kosh\/us-business-to-support-domestic-pharma-firms-growth-and-profitability-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flattrade.in\/kosh\/"},{"@type":"ListItem","position":2,"name":"US business to support domestic pharma firms\u2019 growth and profitability: Report"}]},{"@type":"WebSite","@id":"https:\/\/flattrade.in\/kosh\/#website","url":"https:\/\/flattrade.in\/kosh\/","name":"Flattrade Kosh","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flattrade.in\/kosh\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/flattrade.in\/kosh\/#\/schema\/person\/0df49afdcdc9b8cf2e54f80cbc763e04","name":"Flattrade","url":"https:\/\/flattrade.in\/kosh\/author\/siddharth-aflattrade-in\/"}]}},"_links":{"self":[{"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/posts\/33719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/comments?post=33719"}],"version-history":[{"count":0,"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/posts\/33719\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/media\/33725"}],"wp:attachment":[{"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/media?parent=33719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/categories?post=33719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flattrade.in\/kosh\/wp-json\/wp\/v2\/tags?post=33719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}